California-based Tryp Therapeutics joins other sector leaders with Phase II clinical trials Tryp’s strategy isn’t to steward its drug candidates right through to an FDA approval. Rather, the company hopes to demonstrate their efficacy in the treatment of a range of neuropsychiatric and chronic pain conditions via Phase 2a proof of concept trials, which it understands to be the value inflection…
